| # | Drug | Count |
|---|---|---|
| 0 | BEVACIZUMAB | 29 |
| 1 | ASPIRIN | 17 |
| 2 | ASPIRIN 325 MG | 17 |
| 3 | ASPIRIN 81 MG | 17 |
| 4 | CARBOPLATIN | 16 |
| 5 | CISPLATIN | 15 |
| 6 | PACLITAXEL | 13 |
| 7 | DABIGATRAN ETEXILATE | 12 |
| 8 | DABIGATRAN ETEXILATE MESYLATE | 12 |
| 9 | DEXAMETHASONE | 12 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | OLUTASIDENIB | 3 | 0.0104 |
| 1 | PINDOLOL | 4 | 0.0050 |
| 2 | IXABEPILONE | 2 | 0.0019 |
| 3 | PROTHROMBIN, COAGULATION FACTOR VII HUMAN, COAGULATION FACTOR IX HUMAN, COAGULATION FACTOR X HUMAN, PROTEIN C, PROTEIN S HUMAN, AND WATER | 1 | 0.0018 |
| 4 | BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE | 1 | 0.0016 |
| 5 | CAPSICUM ANNUUM, CETRARIA ISLANDICA, FUCUS VESICULOSUS, GLANDULA SUPRARENALIS SUIS, THYROIDINUM (SUIS), CADMIUM IODATUM, HYDRANGEA ARBORESCENS, PHOSPHORICUM ACIDUM, PHOSPHORUS, PULSATILLA (PRATENSIS), STRONTIUM CARBONICUM, URANIUM NITRICUM, X-RAY | 1 | 0.0010 |
| 6 | TRABECTEDIN | 2 | 0.0009 |
| 7 | PSYLLIUM HUSK | 1 | 0.0007 |
| 8 | CRIZANLIZUMAB | 1 | 0.0007 |
| 9 | FOSTAMATINIB | 5 | 0.0006 |
| # | Drug class | Count |
|---|---|---|
| 0 | Platinum-based Drug [EPC] | 35 |
| 1 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 29 |
| 2 | Corticosteroid [EPC] | 25 |
| 3 | Nonsteroidal Anti-inflammatory Drug [EPC] | 21 |
| 4 | Microtubule Inhibitor [EPC] | 19 |
| 5 | Platelet Aggregation Inhibitor [EPC] | 17 |
| 6 | Nucleoside Metabolic Inhibitor [EPC] | 16 |
| 7 | Alkylating Drug [EPC] | 14 |
| 8 | Proton Pump Inhibitor [EPC] | 12 |
| 9 | beta-Adrenergic Blocker [EPC] | 12 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Interleukin-5 Antagonist [EPC] | 1 | 0.0015 |
| 1 | Selectin Blocker [EPC] | 1 | 0.0007 |
| 2 | Isocitrate Dehydrogenase 1 Inhibitor [EPC] | 1 | 0.0005 |
| 3 | Prostacyclin Receptor Agonist [EPC] | 6 | 0.0002 |
| 4 | Epidermal Growth Factor Receptor Antagonist [EPC] | 10 | 0.0002 |
| 5 | Provitamin D2 Compound [EPC] | 6 | 0.0002 |
| 6 | CD38-directed Cytolytic Antibody [EPC] | 1 | 0.0002 |
| 7 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 29 | 0.0002 |
| 8 | Adenosine Receptor Agonist [EPC] | 1 | 0.0001 |
| 9 | Platinum-based Drug [EPC] | 35 | 0.0001 |